Monoclonal gammopathy of undetermined significance (MGUS) is a condition characterized by the presence of a monoclonal gammopathy without end organ damage.
1 MGUS requires the serum monoclonal (M) protein and bone marrow plasma cells to be less than 3 g/dL and 10% respectively. Most importantly there can be no end organ damage attributable to the plasma cell dyscrasia. Although MGUS is considered a precursor to multiple myeloma (MM), the risk of progression to MM, lymphoproliferative disorder or immunoglobulin light chain (AL) amyloidosis is low which on average is 1%/year.
2,3
Smoldering multiple myeloma (SMM) is defined by a serum M-protein > 3 g/dL or > 10% bone marrow involvement by clonal plasma cells in the absence of end organ damage. 2 The risk of developing MM or AL amyloidosis is significantly higher in patients with SMM as compared to MGUS ranging from 51% at 5 years, 66% at 10 years to 73% at 15 years. Treatment is not recommended until progression to MM which is characterized by CRAB (hypercalcemia, renal impairment, anemia, bone disease) because some patients can remain asymptomatic for years.
2,4-6
Renal impairment is a defining criterion of MM. Aside from a serum creatinine > 2.0 mg/dl attributable to the plasma cell dyscrasia, the current guidelines do not define the renal disease any further. 2, 7 Cast nephropathy, acute tubular necrosis (ATN) due to hypercalcemia or non steroidal antiinflammatory drugs (NSAIDs), AL amyloidosis, monoclonal immunoglobulin deposition disease of the Randall type (MIDD) and light chain proximal tubulopathy (with or without Fanconi Syndrome) have all been described with MM. [8] [9] [10] Other than cast nephropathy and hypercalcemia, MM is not required for the development of the other kidney diseases.
In fact, a growing number of pathologic renal conditions are being attributed to a clonal plasma cell disorder which is less "myeloma-like" and more "MGUS-like" in terms of its bulk and proliferative rate. 11, 12 Unfortunately, the current diagnostic schema fails to properly categorize the hematologic disorder in these patients. Since they do not meet conditions for SMM or MM, these patients are mistakenly diagnosed as MGUS. Terms such as" MIDD with MGUS" or "glomerulonephritis with MGUS" have been used in the literature and diagnosis. [13] [14] [15] Unfortunately, MGUS in this context is misrepresented because in these patients, there is significance to the monoclonal gammopathy; and its significance is not "undetermined." As a matter of fact, despite their non-malignant nature, these diseases are associated with a great deal of morbidity and even mortality. 10, 12, 16 MGUS should not be used to describe hematologic disorders that results in kidney disease. It is due to this necessity that we propose the term "monoclonal gammopathy of renal significance" (MGRS) to discriminate the pathologic nature of these diseases from the truly benign MGUS.
Evidence already supports monoclonal protein as the direct cause of the kidney disease and not the tumor. Bence-Jones proteins isolated from patients with paraprotein related kidney diseases are capable of replicating the kidney disease when injected into animals. 17 In addition, only 15% of AL amyloidosis and 65% of MIDD patients meet criteria for MM. 9, 10 Thus the practice of using malignancy as a prerequisite for treatment in MGRS patients is unnecessary and inappropriate. Nevertheless, many of these patients either receive no treatment or are under-treated. 18 In a large Italian study of MIDD patients, cytotoxic therapy was not prescribed to nearly 30% of those without MM. 10 In those who were treated, none received vincristine-doxorubicin-dexamethasone (VAD) or vincristine-doxorubicinmethylprednisolone (VAMP), the standard therapy for MM at the time. 19 Although the MGUS-like biology sometimes makes the hematologic disease less lethal, the effect on the kidney regrettably is not as benign. A study of 19 MIDD patients (63% with "MGUS") found the 1 year and 5 years patient survival to be 89% and 70% while the renal survival was only 67% and 37% for the corresponding periods. 20 The high rate of end stage renal disease (ESRD) was attributed to the absent or inadequate chemotherapy.
In addition to AL amyloidosis, MIDD and light chain proximal tubulopathy, there are a number of renal diseases now recognized to be associated with MGRS (Table 1) 
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Lymphoma based regimens was found to be effective in 10 of 12 patients with fibrillary glomerulonephritis secondary to lymphoproliferative disorders.
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Treatment of MGRS should be considered even after development of ESRD without other organ involvement if the patient is being considered for kidney transplantation. Hematologic stringent complete response (CR) is the goal of therapy. First, evidence suggests achievement of CR prevents recurrence after kidney transplantation. In MIDD, successful kidney transplantation without recurrence was reported in patients who achieved hematologic CR after ASCT. 53 Similar results have been reported in AL amyloidosis. The recurrence rate of 19 patients was reduced to 10.5% when kidney transplantation was performed in conjunction with ASCT or melphalan and dexamethasone, 56 One recurrence actually occurred prior to definitive treatment. Both hematologic and kidney disease were controlled after a successful ASCT. Another ASCT treated patients had a recurrence 52 months after kidney transplant and was successfully treated with melphalan dexamethasone. Second, achievement of CR in patients with low plasma cell burden and MGUS like proliferative rates appears to be significantly more durable than what is achievable in MM. In a randomized study of single vs double ASCT, the relapse free survival in MM after tandem ASCT was 36 months. 57 In another study, the median time to progression after ASCT was increased to 39 months from 21 months by the addition of lenalidomide as maintenance therapy after ASCT. 58 In comparison, the median time to relapse was estimated at 12.7 years for AL amyloidosis patients who achieved a CR after single ASCT without maintenance. In this population, the median bone marrow plasma cell involvement was 5%. 59 Thus, in patients with low plasma cell burden and proliferative rates, achievement of CR may provide significant advantage in both patient and graft survival after transplantation. 
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